IDEXX Laboratories (IDXX) Receives Buy Rating from Canaccord Genuity

IDEXX Laboratories (NASDAQ:IDXX)‘s stock had its “buy” rating reaffirmed by equities researchers at Canaccord Genuity in a research note issued to investors on Monday. They currently have a $210.00 price target on the stock. Canaccord Genuity’s target price points to a potential upside of 12.40% from the stock’s current price.

IDXX has been the topic of a number of other research reports. Piper Jaffray Companies began coverage on shares of IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 target price on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $181.71.

IDEXX Laboratories (NASDAQ:IDXX) traded down $0.19 during mid-day trading on Monday, hitting $186.84. 157,623 shares of the company’s stock were exchanged, compared to its average volume of 478,261. IDEXX Laboratories has a 12-month low of $119.84 and a 12-month high of $187.43. The stock has a market capitalization of $16,312.52, a PE ratio of 60.39, a price-to-earnings-growth ratio of 2.08 and a beta of 0.42. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. research analysts expect that IDEXX Laboratories will post 3.23 EPS for the current fiscal year.

In related news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total transaction of $2,670,300.00. Following the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $157,929,404.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the sale, the chairman now directly owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The disclosure for this sale can be found here. Insiders have sold 130,160 shares of company stock worth $20,019,685 in the last three months. 2.77% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of IDXX. D.A. Davidson & CO. boosted its stake in IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares in the last quarter. Sun Life Financial INC boosted its stake in IDEXX Laboratories by 9,085.7% during the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares in the last quarter. BB&T Investment Services Inc. bought a new stake in IDEXX Laboratories during the second quarter worth about $104,000. Zions Bancorporation bought a new stake in IDEXX Laboratories during the third quarter worth about $162,000. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after acquiring an additional 1,000 shares in the last quarter. 86.54% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “IDEXX Laboratories (IDXX) Receives Buy Rating from Canaccord Genuity” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/29/idexx-laboratories-idxx-receives-buy-rating-from-canaccord-genuity.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply